Summary
72%
|
Pharmacokinetic
|
0% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aldesleukin | |||||||||||
| Scores | 0% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
QT time prolongation
| |||||||||||
|
Anticholinergic effects
| |||||||||||
|
Serotonergic effects
| |||||||||||
|
Adverse drug events
|
-28% | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Diarrhea | |||||||||||
| Shivering | |||||||||||
| Vomiting | |||||||||||
Variants ✨
For the computationally intensive evaluation of the variants, please choose the paid standard subscription.
Intended use
Aldesleukin is used to treat metastatic (spread) kidney cancer when the kidney has had to be removed. It is infused intravenously or subcutaneously as a solution. Aldesleukin is a genetically modified variant of human interleukin-2 (IL-2), also known as T-cell growth factor. As part of the so-called cellular immune system, T cells also attack cancer cells and destroy them. Like the natural IL-2, aldesleukin increases the activity of T cells and thus has a growth-inhibiting and killing effect on tumor tissue. The exact mechanism has not been conclusively clarified. Unwanted effects can include flu-like symptoms, low blood pressure, anxiety, changes in the blood count (e.g. leukopenia), reduced kidney and lung function, shortness of breath or fluid retention (edema).
Pharmacokinetics
-0%
| ∑ Exposurea | ald | |
|---|---|---|
| Aldesleukin | 1 |
Symbol (a): x-fold change in AUC
Legend (n.a.): Information not available
Legend (n.a.): Information not available
Since only aldesleukin was entered without any further substances, no pharmacokinetic interactions can be detected.
Rating:
The pharmacokinetic parameters of the average population are used as the starting point for calculating the individual changes in exposure due to the interactions.
The bioavailability of aldesleukin is unknown. Protein binding [Pb] is not known. The metabolism does not take place via the common cytochromes.
Serotonergic effects
-0%
| Scores | ∑ Points | ald |
|---|---|---|
| Serotonergic Effects a | 0 | Ø |
Symbol (a): Increased risk from 5 points.
Rating: According to our knowledge, aldesleukin does not increase serotonergic activity.
Anticholinergic effects
-0%
| Scores | ∑ Points | ald |
|---|---|---|
| Kiesel b | 0 | Ø |
Symbol (b): Increased risk from 3 points.
Rating: According to our findings, aldesleukin does not increase anticholinergic activity.
QT time prolongation
-0%
We do not know of any QT-prolonging potential for aldesleukin.
General adverse effects
-28%
| Side effects | ∑ frequency | ald |
|---|---|---|
| Diarrhea | 67.0 % | 67.0 |
| Shivering | 52.0 % | 52.0 |
| Vomiting | 50.0 % | 50.0 |
| Rash | 42.0 % | 42.0 |
| Hyperbilirubinemia | 40.0 % | 40.0 |
| Thrombocytopenia | 37.0 % | 37.0 |
| Nausea | 35.0 % | 35.0 |
| Dyspnea | 35.0 % | 35.0 |
| Confusion | 34.0 % | 34.0 |
| Elevated serum creatinine | 33.0 % | 33.0 |
Tabular extract of the most common side effects
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Sign (+): side effect described, but frequency not known
Sign (↑/↓): frequency rather higher / lower due to exposure
Hematological
Anemia (29%): aldesleukin
Systemic
Fever (29%): aldesleukin
Malaise (27%): aldesleukin
Cardiac
Peripheral edema (28%): aldesleukin
Tachycardia (23%): aldesleukin
Myocardial infarction: aldesleukin
Hypotension: aldesleukin
Supraventricular tachycardia: aldesleukin
Dermatological
Pruritus (24%): aldesleukin
Neurological
Asthenia (23%): aldesleukin
Somnolence (22%): aldesleukin
Gastrointestinal
Loss of appetite (20%): aldesleukin
Vascular
Capillary leak syndrome: aldesleukin
Limitations
Based on your
References
No literature information available.
